10/670,596

STM STRUCTURE SEARCH 5-25-04

=> d ibib abs hitstr 1-9

inventors

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:287780 CAPLUS
DOCUMENT NUMBER: 140:303543
TITLE: Preparation of piperidine- and tetrazolyl-containing ureas and related compounds as modulators of chemokine receptor activity
INVENTOR(S): Batt, Douglas G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028530	A1	20040408	WO 2003-US30256	20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004067935	A1	20040408	US 2003-670596	20030925

PRIORITY APPLN. INFO.: US 2002-413895P P 20020926
GI



I



II

AB The present application describes modulators of chemokine receptors (no data) (shown as I; variables defined below; e.g. II) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases (no data). Although the methods of preparation are not claimed, >15 example prepns. and characterization data for .apprx.60 examples of I are included. For example, II was prepared in 3 steps (96,



RN 676621-97-9 CAPLUS
CN 3-Piperidinemethanamine, 1-[3-(4-fluorophenyl)-2,2-dimethyl-1-oxopropyl]-N-[[[3-(1-methyl-1H-tetrazol-5-yl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 676622-21-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[[[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]amino]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:836848 CAPLUS
DOCUMENT NUMBER: 139:350754
TITLE: Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer
INVENTOR(S): Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.; Manley, Peter J.; Wu, Zhicai; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086394	A1	20031023	WO 2003-US10442	20030404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-370847P P 20020408
US 2002-417174P P 20021009

OTHER SOURCE(S): MARPAT 139:350754
GI



I



II

AB The title compds. comprising a 2,3-diphenylquinoxaline moiety [I; u, v, w and x = CH, N; y, z = CH, N (provided that at least one of y and z = N); Q = NR5R6, (un)substituted aryl, heterocyclyl; R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl; or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5, R6 = H, aryl, heterocyclyl, etc.; or NR5R6 = monocyclic or bicyclic heterocycle; R7 = halo, CN, CO2H, etc.; n = 0-3; p = 0-2; t = 2-6; m = 0-2; q = 0-4; r =

0-1] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared E.g., a 2-step synthesis of the quinoxaline II [starting from 4-bromomethylbenzil and 4-(2-keto-1-benzimidazolinyl)piperidine], was given. The exemplified compds. I were found to have IC50 of ≤ 50 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.

IT **616867-75-5P 616867-76-6P 616867-77-7P**
616867-78-8P 616867-79-9P 616867-80-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,3-diphenylquinoxaline derivs. as inhibitors of Akt activity for treating cancer)

RN 616867-75-5 CAPLUS
CN Urea, N-(3-fluorophenyl)-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-76-6 CAPLUS
CN Urea, N-(3-fluorophenyl)-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-75-5
CMF C34 H32 F N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616867-77-7 CAPLUS
CN Urea, N-phenyl-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-78-8 CAPLUS
CN Urea, N-phenyl-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-77-7
CMF C34 H33 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616867-79-9 CAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 616867-80-2 CAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-piperidinyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616867-79-9
CMF C35 H34 Br N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:830896 CAPLUS
DOCUMENT NUMBER: 135:357846
TITLE: Preparation of ethylenediamine compound libraries as drugs
INVENTOR(S): Swayze, Eric Edward; Jefferson, Elizabeth Anne Campbell
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA
SOURCE: U.S., 26 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6316623	B1	20011113	US 1998-138186	19980821

PRIORITY APPLN. INFO.: US 1998-138186 19980821
OTHER SOURCE(S): MARPAT 135:357846

AB R5Z(CH2)pNR4CHR2CHR1NR3R6 [I; R1,R2 = H, alkyl, (hetero)aryl(alkyl), etc.; R3-R5 = H, amino-protective group, alkyl, alkanoyl, etc.; R6 = H or linked support; Z = azacycloalkylene; p = 0-3] were prepared Thus, RNTsCH2CH2NHSO2C6H4(NO2)-2 (R = linked resin, Ts = tosyl) was condensed with N-protected piperidine-4-methanol (preparation each given) and the product converted in 5 steps to PhCH2CO2CH2N(COC6H4Me-3)CH2CH2NHTs (Z = piperidine-1,4-diyl). Data for biol. activity of I were given.

IT **372947-22-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ethylenediamine compound libraries as drugs)

RN 372947-22-3 CAPLUS
CN 3-Piperidinemethanamine, N-[[(4-methylphenyl)amino]carbonyl]-N-[2-[[[(4-methylphenyl)amino]carbonyl]amino]ethyl]-1-[(tetrahydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:742068 CAPLUS
DOCUMENT NUMBER: 133:281698
TITLE: Preparation of N-piperidinylethyl-N'-cyclohexylethyl-N'-acetylthioethylurea derivatives as TNF-α production inhibitors and useful in treatment of autoimmune diseases
INVENTOR(S): Mita, Shiro; Horiuchi, Masato; Ban, Masakazu; Suhara, Hiroshi

PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061552	A1	20001019	WO 2000-JP2267	20000407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000351764	A2	20001219	JP 2000-105901	20000407
EP 1172359	A1	20020116	EP 2000-915410	20000407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002077357	A1	20020620	US 2001-969589	20011004
US 6534499	B2	20030318		

PRIORITY APPLN. INFO.: JP 1999-100482 A 19990407
WO 2000-JP2267 W 20000407

OTHER SOURCE(S): MARPAT 133:281698

GI



I

AB Title compound I, derivs., analogs, and medicinally acceptable salts are prepared having TNF-α production inhibiting effects and effective in treatment of autoimmune diseases. Thus, the title compound I was prepared and tested.

IT **300577-67-7P 300578-05-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea derivs. as TNF-α production inhibitors and useful in treatment of autoimmune diseases)

RN 300577-67-7 CAPLUS

CN Urea, N-(2-cyclohexylethyl)-N-(2-hydroxyethyl)-N'-[(1-methyl-3-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300578-05-6 CAPLUS
CN Ethanethioic acid, S-[2-[(2-cyclohexylethyl)[[[(1-methyl-3-piperidinyl)methyl]amino]carbonyl]amino]ethyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691093 CAPLUS
DOCUMENT NUMBER: 131:310284
TITLE: Preparation of substituted diamines as α4β1 mediated cell adhesion inhibitors
INVENTOR(S): Mccarthy, Clive; Harris, Neil Victor; Morley, Andrew David
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Limited, UK
SOURCE: PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954321	A1	19991028	WO 1999-GB1230	19990421
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9937164	A1	19991108	AU 1999-37164	19990421

PRIORITY APPLN. INFO.:

GB 1998-8431	A	19980421
GB 1998-11417	A	19980528
US 1998-104139P	P	19981014
US 1998-104238P	P	19981014
WO 1999-GB1230	W	19990421

OTHER SOURCE(S): MARPAT 131:310284
GI



I



II

AB Substituted diamines (I) [wherein R1 = lower alkyl or various combinations of substituents, such as (cyclo)alkyl, (cyclo)alkenyl, (cyclo)alkynyl, (hetero)aryl(alkyl), etc., and linkage groups, such as C(O), C(S), (un)substituted NHC(O) or NHC(S), S(O), SO2, heteroaryldiyl, heterocycloalkylene, phenylene, etc.; R2 = H or lower alkyl; R3 and R4 = independently H or (un)substituted alkyl, alkenyl, or alkynyl; or R3 and R4 together may = (CH2)n or C(O)CH:CH; L1 = alkylene or (un)substituted (CHR10)pAr(CHR10)p; or L1N(R3) = (un)substituted alkylheterocyclo; or N(R2)L1 = (un)substituted heterocycloalkyl; or N(R2)L1N(R3) = diaza heterocyclo; L2 = (un)substituted alkylene, alkenylene, alkynylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene; Y = carboxy (or an acid bioisostere) or (un)substituted C(O)NH2; Ar = phenylene, (hetero)cycloalkylene, or heteroaryldiyl; R10 = H or lower alkyl; m = 0 or 1; n = 2-4; p = 0-3] were prepd by solid phase synthesis as α4β1 mediated cell adhesion inhibitors. For example, the ureido derivative (II) was prepared using a Wang resin support. The resin was loaded with acryloyl chloride and treated sequentially with 1-(3-aminopropyl)-2-pyrrolidinone, triphosgene, homopiperazine, and 3-methoxy-4-[3-(2-methylphenyl)ureido]phenylacetic acid to yield II. Compds. of formula I regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1). Particular compds. of the invention suppressed cell adhesion to fibronectin and VCAM-1 with IC50 values ranging from 100μM to 1 nM in assays on metabolically labeled RAMOS cells. Particular compds. also inhibited airway inflammation after antigen challenge in mice and rats. The inhibitors caused a statistically significant reduction in eosinophil and lymphocyte nos. in bronchoalveolar lavage (BAL) and airway tissue. The invention compds., their prodrugs, pharmaceutically acceptable salts, and solvates, are useful for the treatment of inflammatory diseases and asthma.

IT **247253-46-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted diamines as α4β1 mediated cell adhesion inhibitors for treatment of inflammatory diseases and asthma)

RN 247253-46-9 CAPLUS

CN Benzeneacetic acid, 4-[[[[[1-[[3-methoxy-4-[[[(2-

methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-
piperidinyl]methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:332965 CAPLUS
DOCUMENT NUMBER: 131:44643
TITLE: Preparation of phenol derivatives as antioxidants and ACAT inhibitors
INVENTOR(S): Suzuki, Toshikazu; Ohmizu, Hiroshi; Hashimura, Yoshitada; Kubota, Hitoshi; Tanaka, Keiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11139969	A2	19990525	JP 1998-220951	19980805

PRIORITY APPLN. INFO.: JP 1997-212376 19970807
OTHER SOURCE(S): MARPAT 131:44643
GI



I



II

AB The title compds. I [R = H, (un)substituted alkyl, etc.; R1 = (un)substituted alkyl; R2 = (un)substituted alkyl, etc.; OR3= (protected) OH; R4 = H, (un)substituted alkyl, etc.; W = O, etc.; NR5R6 = (mono- or disubstituted) amino, etc.] are prepared The title compound II in vitro showed IC50 of 0.000067 μM against ACAT.

IT **195314-27-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenol derivs. as antioxidants and ACAT inhibitors)

RN 195314-27-3 CAPLUS

CN Pyridinium, 3-[[[[[3-(1,1-dimethylethyl)-2-hydroxy-5-methoxyphenyl]amino]carbonyl]amino]methyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:631334 CAPLUS
DOCUMENT NUMBER: 129:260350

TITLE: Preparation of (hetero)arylthioureas and analogs as amyloid β-protein biosynthesis inhibitors
INVENTOR(S): Heinz, Lawrence J.; Panetta, Jill A.; Phillips, Michael L.; Reel, Jon K.; Shadle, John K.; Simon, Richard L.; Whitesitt, Celia A.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5814646	A	19980929	US 1995-398188	19950302

PRIORITY APPLN. INFO.: US 1995-398188 19950302
OTHER SOURCE(S): MARPAT 129:260350
GI



II

AB R1L1Y1C(:Z)Y2L2R2 [I; R1 = (un)substituted (hetero)aryl; R2 = cycloalkyl, heterocyclyl, (un)substituted (hetero)aryl; R2 may addnl. = H when L2 = alkylene; L1,L2 = bond or [phenyl(alkyl)] alkylene; 1 of Y1,Y2 = NR3 and the other = O, S, NR3; R3 = H, OH, alkyl, alkoxy, dialkylamino; Z = O or S] were prepared Thus, 2-chloroquinoline was thioetherified by 4-(HS)C6H4NH2 and the product amidated by 4,3-Cl(F3C)C6H3NCS to give title compound II. Data for biol. activity of I were given.

IT **213691-47-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylthioureas and analogs as amyloid β-protein biosynthesis inhibitors)

RN 213691-47-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[[[4-[4-(1,1-dimethylethyl)phenoxy]phenyl]amino]thioxomethyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:589063 CAPLUS
DOCUMENT NUMBER: 127:234183
TITLE: Ureidophenols as ACAT inhibitors and antioxidants
INVENTOR(S): Suzuki, Toshikazu; Ohmizu, Hiroshi; Hashimura, Yoshimasa; Kubota, Hitoshi; Tanaka, Keiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 790240	A1	19970820	EP 1997-102315	19970213
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2197364	AA	19970816	CA 1997-2197364	19970212
JP 10195037	A2	19980728	JP 1997-28582	19970213
US 5849732	A	19981215	US 1997-800680	19970214
CN 1165815	A	19971126	CN 1997-101973	19970217

PRIORITY APPLN. INFO.: JP 1996-28083 19960215
JP 1996-300032 19961112
OTHER SOURCE(S): MARPAT 127:234183
GI



I



II

AB Ureidophenols I [R = H, alkyl, alkyloxy; R1 = alkyl; R2 = alkyl, alkoxy; R3 = H, alkyl, acyl; W = O, S or NR6; NR4R5 = (un)substituted NH2, N heterocycle; R6 = H, alkyl, aryl, OH, alkoxy] were prepared I possess both an ACAT inhibitory activity and an antioxidative activity (no data). Thus, 4,2-MeO(Me3C)C6H3OH was treated with 4-MeOC6H4NH2 to give the azobenzene II [R7 = N:NC6H4OMe-4], which was O-protected, reduced to the amine, treated with PhNCO, and O-deprotected to give the ureidophenol II [R7 = NHCONHPh].

IT **195314-27-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureidophenols as ACAT inhibitors and antioxidants)

RN 195314-27-3 CAPLUS
CN Pyridinium, 3-[[[[[3-(1,1-dimethylethyl)-2-hydroxy-5-methoxyphenyl]amino]carbonyl]amino]methyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1978:136425 CAPLUS
DOCUMENT NUMBER: 88:136425
TITLE: Studies on quaternary pyridinium salts, VII. Quaternary pyridinium salts with urea or carbamate group. Preparation of betaines
AUTHOR(S): Guendel, Wolf Hellmut
CORPORATE SOURCE: Chem. Lab., Univ. Freiburg, Freiburg/Br., Fed. Rep. Ger.
SOURCE: Zeitschrift fuer Naturforschung, Teil B: Anorganische Chemie, Organische Chemie (1978), 33B(1), 84-8
CODEN: ZNBAD2; ISSN: 0340-5087
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB Pyridinium salts I and II (R1 = SO2NH2, NHCONHPh, NHCONHCH2OMe, NHCO2Et, NHCONH2, CH2NHCONHPh, R2 = MeOCH2, Pr, PhCH2, 2,6-Cl2C6H3CH2; R3 = NHCONHCH2OMe, NHCONHPh, CONH2 (14 compds) were prepared and their activity consts. determined On addition of base some stable inner salts could be isolated.

IT **66073-64-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66073-64-1 CAPLUS
CN Pyridinium, 1-[(2,6-dichlorophenyl)methyl]-3-[[[(phenylamino)carbonyl]amino]methyl]-, chloride (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 11:58:42 ON 25 MAY 2004)

     FILE 'REGISTRY' ENTERED AT 11:58:47 ON 25 MAY 2004
L1                STRUCTURE UPLOADED
L2             50 S L1
L3                STRUCTURE UPLOADED
L4              3 S L3
L5             76 S L3 FULL

     FILE 'CAPLUS' ENTERED AT 12:02:54 ON 25 MAY 2004
L6              9 S L5

=> d l3
L3 HAS NO ANSWERS
L3                 STR
```



G1 C,O,S,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=>